HTR1A and Parkinson disease: The interaction with the σ receptors might be relevant for the treatment of PD, since the σ1 receptor antagonist and 5-HT1A receptor agonist BMY-14802 was demonstrated to reduce abnormal involuntary movements (AIMs) in the L-DOPA-treated 6-OHDA-lesioned rat [130, 131].